Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 308 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Galmed Pharmaceuticals Ltd | GLMD | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.02 | 5.28% | 0.399 | 06:00:04 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.379 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 7 | 308 | - | 0.26 - 7.80 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 04:04:35 | 5 | US$ 0.40 | USD |
Galmed Pharmaceuticals Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 638.4k | 1.68M | - | 0 | -6.91M | -4.11 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Galmed Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLMD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.3613 | 0.40 | 0.35 | 0.3823052 | 44,316 | 0.0377 | 10.43% |
| 1 Month | 0.3208 | 0.44 | 0.315 | 0.3750264 | 256,380 | 0.0782 | 24.38% |
| 3 Months | 0.3696 | 0.4688 | 0.30 | 0.3527643 | 219,495 | 0.0294 | 7.95% |
| 6 Months | 0.3758 | 0.47 | 0.26 | 0.3706044 | 195,896 | 0.0232 | 6.17% |
| 1 Year | 4.6395 | 7.80 | 0.26 | 1.95 | 230,744 | -4.24 | -91.40% |
| 3 Years | 51.30 | 61.20 | 0.26 | 17.12 | 170,888 | -50.90 | -99.22% |
| 5 Years | 117.15 | 121.50 | 0.26 | 34.85 | 154,969 | -116.75 | -99.66% |
Galmed Pharmaceuticals Description
| Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |
